ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0309

Diagnostic Delay in Psoriatic Arthritis: A Population Based Study

Paras Karmacharya1, Kerry Wright2, Sara J. Achenbach3, Delamo Bekele2, Cynthia Crowson4, Alexis Ogdie5, Ali Duarte-Garcia2, Floranne C. Ernste3, Megha M. Tollefson1 and John Davis2, 1Mayo Clinic, Rochester MN, ROCHESTER, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 5University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2020

Keywords: population studies, Psoriatic arthritis, Spondylarthropathies

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is important for improving long-term outcomes. Trends in diagnostic delay of PsA in the US and factors associated with delay in diagnosis have not been well studied. The aim of our study was to 1) examine the diagnostic delay in PsA in residents of a geographically defined area from 2000-17, and 2) identify demographic and clinical characteristics associated with diagnostic delay in PsA.

Methods: A retrospective, population-based cohort of incident PsA patients ≥18 years of age from a geographically defined area meeting ClASsification of Psoriatic ARthritis (CASPAR) criteria for PsA (2000-17) was identified. Disease onset was taken as onset of any PsA related joint symptom as reported by the patient and documented by a physician in the medical records. PsA diagnosis date was the date of confirmatory diagnosis of PsA by a physician/rheumatologist. Diagnostic delay was defined as the time from disease onset to a diagnosis of PsA.  Logistic regression models adjusted for age and sex were performed to identify factors associated with delay in PsA diagnosis.

Results: There were 162 incident PsA cases from 2000-17.  Mean age was 41.5 (SD=12.6) and 46% were females. Median lag time from disease onset (PsA related joint symptoms) to first confirmatory diagnosis by a physician was 2.5 years (interquartile range=0.5, 7.3). At six months 23% (n=38) of the cohort received a confirmatory diagnosis of PsA, 35% (n=56) at one year and 45% (n=73) at two years of symptom onset respectively. No significant trend in diagnostic delay were observed. PsA patients with younger age at diagnosis, higher body mass index (BMI), and enthesitis before diagnosis, were associated with a diagnostic delay of greater than one and two years, while sebopsoriasis at diagnosis was associated with a lower likelihood of delay (Table 1). No significant association with sex, education level, smoking status, alcohol intake, psoriasis severity or location, nail involvement, family history of psoriasis or PsA, history of extra-articular manifestations (i.e., uveitis, inflammatory bowel disease), or high inflammatory markers at the time of diagnosis was found. Logistic regression models adjusted for age and sex showed a higher likelihood of radiographic damage at PsA diagnosis with a delay in diagnosis of six months, one year and two years, however these associations did not reach statistical significance (Table 2).

Conclusion: In this population-based study, more than half of PsA patients had a delay in diagnosis two or more years, and no significant improvement in time to diagnosis was noted from 2000-17. Patients with younger age at diagnosis, higher BMI, or enthesitis before diagnosis were more likely to have a diagnostic delay of more than two years while patients with sebopsoriasis were less likely to have a diagnostic delay. Radiographic damage may be associated with diagnostic delay, but this association did not reach statistical significance, perhaps due to the limited sample size of the cohort.

Table 1. Baseline characteristics of PsA patients with delay in diagnosis < 2 years compared to ≥2 years

Table 2. Logistic models for delay in PsA diagnosis adjusted for age and sex


Disclosure: P. Karmacharya, National Center for Advancing Translational Science, 2, SPARTAN (Spondyloarthritis Research and Treatment Network), 2; K. Wright, None; S. Achenbach, None; D. Bekele, None; C. Crowson, Myriad Genetics, 1, Pfizer, 1; A. Ogdie, abbvie, 1, amgen, 1, bms, 1, celgene, 1, corona, 1, lilly, 1, janssen, 1, novartis, 1, 2, novartis, 1, pfizer, 1; A. Duarte-Garcia, None; F. Ernste, None; M. Tollefson, None; J. Davis, Pfizer, 2, AbbVie, 5, 8, Sanofi-Genzyme, 5, 8.

To cite this abstract in AMA style:

Karmacharya P, Wright K, Achenbach S, Bekele D, Crowson C, Ogdie A, Duarte-Garcia A, Ernste F, Tollefson M, Davis J. Diagnostic Delay in Psoriatic Arthritis: A Population Based Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/diagnostic-delay-in-psoriatic-arthritis-a-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-delay-in-psoriatic-arthritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology